Mednovators

A Science and Technology Intelligence Hub on a mission for better health outcomes. We are innovating for bold and groundbreaking solutions. We have assembled passionate minds that span from novice to retired, both from academia and industry, to apply our diligence model for rigor and speed. Combined, we have 100+ years of pharmaceutical and technical expertise, including creating diverse drug modalities, launching successful medicines and businesses, and clinical practice. Single target medicines alone, are not enough to stop cancer and immune related deaths. The complex network of immune-related mechanisms requires a blend of a much larger number of molecules, than we have ever imagined, to treat all underlying factors simultaneously to avoid adaptive drug resistance and ensure sustained efficacy. Our goal is to re-evolve therapies with our innovative 360-degree pharmaceutical and AI assisted diligence model in accelerating a pipeline of adjuvants to improve BioPharma's efficacy in mitigating these deaths. This includes various modalities (small-molecules, nucleic acids, monoclonal and bi-specific antibodies, recombinant proteins, antibody-drug conjugates, vaccines, cell-gene therapies, and many more). We partner with medical companies to accelerate groundbreaking combination therapies to the millions of patients who are longing for hope. We scout for adjuvants globally, produce them in a safe way, and provide due diligence to understand the therapeutic potentials of your product. We identify targeted medicines that could benefit from adjuvants for increased effectiveness. Our scope includes functions of CMC (process, analytical, GMP manufacturing, quality assurance, regulatory, etc.) to increase the clinical efficacy of your single-target medicines. Our team works with patient-centric speed and settling for nothing less. Contact us today to assist with research, pre-clinical, clinical, market authorization, and product lifecycle investigation.